GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entera Bio Ltd (NAS:ENTX) » Definitions » Forward Dividend Yield %

Entera Bio (Entera Bio) Forward Dividend Yield % : 0.00% (As of May. 01, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Entera Bio Forward Dividend Yield %?

As of today (2024-05-01), the Forward Annual Dividend Yield of Entera Bio is 0.00%.

As of today (2024-05-01), the Trailing Annual Dividend Yield of Entera Bio is 0.00%.

ENTX's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.5
* Ranked among companies with meaningful Forward Dividend Yield % only.

Entera Bio's Dividends per Share for the three months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Entera Bio's Forward Dividend Yield %

For the Biotechnology subindustry, Entera Bio's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entera Bio's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entera Bio's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Entera Bio's Forward Dividend Yield % falls into.



Entera Bio Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Entera Bio  (NAS:ENTX) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Entera Bio Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Entera Bio's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Entera Bio (Entera Bio) Business Description

Traded in Other Exchanges
Address
Minrav Building - Fifth Floor, Kiryat Hadassah, Jerusalem, ISR, 9112002
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Executives
Haya Taitel director KIRYAT HADASSAH, MINRAV BUILDING, 5TH FLOOR, JERUSALEM L3 9112002
Miranda Jayne Toledano director C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135
Gerald M Lieberman director C/O ALLIANCE CAPITAL, 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Sean Ellis director KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Dana Yaacov-garbeli officer: Israel CFO KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Phillip Schwartz director, officer: President of R&D C/O ENTERA BIO LTD., KIRYAT HADASSAH, MINRAV BUILDING, 5TH FL, JERUSALEM L3 9112002
Ramesh Ratan officer: U.S.based CFO KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Ron Mayron director 22A ORANIM ST, HOD HASHARON L3 4526333
Spiros Jamas director, officer: Chief Executive Officer
Gerald M Ostrov director 41 WATERVIEW, LONG BRANCH NJ 07740
Yonatan Malca director KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Roger Garceau director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Hillel Galitzer officer: Chief Operating Officer KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Santora Arthur C Ii officer: Chief Medical Officer KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002

Entera Bio (Entera Bio) Headlines

From GuruFocus

Entera Bio Regains Compliance with Nasdaq Listing Requirements

By sperokesalga sperokesalga 03-23-2023